Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (GXCPC1) for Knee Osteoarthritis

Phase 1

Completed

• Conditions: Knee Osteoarthritis
• Interventions: Drug: GXCPC1; Device: HA

• Registration Number: NCT03943576
• Lead Sponsor: Gwo Xi Stem Cell Applied Technology Co., Ltd.

Brief Summary

The aim of the investigators study was to investigate the safety and efficacy of allogeneic ADSCs for the clinical treatment of knee osteoarthritis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-01-23
• Study First Submitted QC: 2019-05-08
• Study First Posted: 2019-05-09
• Study Start: 2019-12-01
• Primary Completion: 2022-04-27
• Study Completion: 2023-03-22
• Status Verified: 2023-06
• Last Update Submitted: 2023-06-05
• Last Update Posted: 2023-06-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

1. Provision of signed and dated informed consent form
2. Aged 40 to 80 years old (inclusive)
3. Kellgren-Lawrence grading II-IV, as determined by American College ofRheumatology (ACR) criteria for osteoarthritis of the knee
4. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score of 7 ~ 17 (inclusive) in the target knee despite use of NSAID
5. Contraindicated to long term systemic NSAID (e.g. suffer from severe gastrointestinal side effects upon systemic NSAID administration, or due to underlying increased gastrointestinal, cardiovascular, or renal risk) and not able to receive or wish to delay knee arthroplasty

Exclusion Criteria

1. With previous surgery of articular fracture, ligament reconstruction, meniscal reconstruction, and knee arthroplasty on the target knee joint

2. With previous intra-articular intervention (e.g. steroid, anesthetics, hyaluronate, arthroscopic surgery) on the target knee joint 12 weeks prior to screening

3. Administered or required systemic or local on the target knee joint immunosuppressive agent, anti-inflammatory drug, steroid, analgesics, opioid, or duloxetine for OA knee except for acetaminophen and NSAID within 1 week prior to screening

4. With joint diseases other than knee osteoarthritis considered by investigator not eligible to enter the study

5. Unable to receive MRI examination, including allergic to the contrast medium for MRI used in the study, with known history of claustrophobia, having any existing metallic intraocular foreign body or active/inactive implanted medical devices, such as cardiac pacemaker, cochlear, intracranial vascular clips or neurostimulator

6. Active or suspected infection of the target knee joint

7. History of human immunodeficiency virus (HIV) infection

8. History of malignancy within 2 years prior to screening

9. With body mass index (BMI) greater or equal to 35 kg/m2

10. Known hypersensitivity to any component of the investigational product or the active control

11. Participated other investigational study within 4 weeks prior to screening

12. With ongoing or within the past 2 years serious medical conditions (e.g. concomitant illness) such as cardiovascular (e.g. New York Heart Association grade III or IV), hepatic (e.g. Child-Pugh Class C), psychiatric condition (e.g. alcoholism, drug abuse), medical history, physical findings, or laboratory abnormality that in the investigators' opinion could interfere with the results of the trial or adversely affect the safety of the subject

13. Female subject with childbearing potential who is lactating or has positive serum or urine pregnancy test at Screening

14. Subject with childbearing potential refuses to use highly effective contraceptives from signing informed consent until Final/Early Termination Visit. At least two forms of birth control must be adopted and one of which must be a barrier method. Acceptable forms include:

    • Established use of oral, injected or implanted hormonal methods of contraception
    • Placement of an intrauterine device (IUD) or intrauterine system (IUS)
    • Barrier methods of contraception: condom, or occlusive cap (diaphragmor cervical/vault caps)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
GXCPC1	GXCPC1	GXCPC1 contains 6.7×10\^6 or 4×10\^7 allogeneic adipose-derived stem cells (ADSCs) in 3 mL
hyaluronic acid	HA	Hya Joint Plus synovial fluid supplement 3mL

Primary Outcome Measures

Name	Time	Method
WOMAC pain score	week 24	Change from baseline in WOMAC pain score at Week 24

Secondary Outcome Measures

Name	Time	Method
MRI	week 0, 24, 48	Change from baseline to post-treatment visits on the target knee in MRI examination results
Visual Analogue Scale (VAS)	week 0, 1, 4, 12, 24	Changes from baseline to post-treatment visits on the target knee in Visual Analogue Scale (VAS) for pain
12-item Short Form (SF-12)	week 0, 1, 4, 12, 24	Change from baseline to post-treatment visits in total score of 12-item Short Form (SF-12) health survey questionnaire

Trial Locations

Locations (1)

GWOXI Stem Cell Applied Technology Co., Ltd.; 🇨🇳 Hsinchu, Taiwan